林业发展局核准为抗药性淋病提供新的口服抗生素Zoliflodacin,预计2026年底供应。 FDA approves new oral antibiotic zoliflodacin for drug-resistant gonorrhea, with availability expected in late 2026.

林业发展局批准了Zoliflodacin,这是一种新的口服抗生素,用于治疗12岁及12岁以上的病人中不复杂的泌尿素性淋病,这标志着数十年来的首次新治疗。 The FDA has approved zoliflodacin, a new oral antibiotic, for treating uncomplicated urogenital gonorrhea in patients 12 and older, marking the first new treatment in decades. 它对耐药菌株有效,包括对和亚胺素耐药的菌株,并以单次3克剂量给予. It is effective against drug-resistant strains, including those resistant to ceftriaxone and azithromycin, and is given as a single 3-gram dose. 根据有930人参加的第3阶段试验核准,其治疗率与目前的治疗方法相似。 Approved based on a phase 3 trial with 930 participants, it showed similar cure rates to current treatments. 预计该药物将于2026年底提供。 The drug is expected to be available in late 2026. 大约在同一时间,还批准了第二个抗生素(gepotidacin)。 A second antibiotic, gepotidacin, was also approved around the same time. 批准被视为解决抗药性淋病不断上升问题的关键步骤,这种疾病影响到全球数百万人,被世卫组织列为优先病原体。 The approvals are seen as critical steps in addressing rising drug-resistant gonorrhea, which affects millions globally and is classified as a priority pathogen by the WHO.